Surender Khurana

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, Food and Drug Administration, Bethesda, MD 20892, USA Electronic address
    Vaccine 32:2188-97. 2014
  2. pmc DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults
    Surender Khurana
    Division of Viral Products, National Institute of Allergyand Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 208:413-7. 2013
  3. pmc AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, Food and Drug Administration FDA, Bethesda, Maryland, USA
    PLoS Pathog 8:e1002920. 2012
  4. pmc H5N1-SeroDetect EIA and rapid test: a novel differential diagnostic assay for serodiagnosis of H5N1 infections and surveillance
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bldg 29B, Rm 4NN02, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 85:12455-63. 2011
  5. pmc Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies
    Swati Verma
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    J Virol 86:12283-93. 2012
  6. pmc Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Virol 85:1246-56. 2011
  7. pmc H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Virol 85:10945-54. 2011
  8. ncbi request reprint Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, MD 20892, USA
    Sci Transl Med 5:200ra114. 2013
  9. pmc Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 43:304-12. 2006
  10. doi request reprint Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Sci Transl Med 2:15ra5. 2010

Detail Information

Publications24

  1. ncbi request reprint Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, Food and Drug Administration, Bethesda, MD 20892, USA Electronic address
    Vaccine 32:2188-97. 2014
    ..Importantly, there was a good agreement between HA content determined by the SPR-based potency assay and the traditional SRID assay. ..
  2. pmc DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults
    Surender Khurana
    Division of Viral Products, National Institute of Allergyand Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 208:413-7. 2013
    ..Enhanced HA1 binding and avidity after an interval of ≥12 weeks between prime and boost correlated with improved neutralization of homologous and heterologous H5N1 strains. Clinical trials registration NCT01086657. ..
  3. pmc AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, Food and Drug Administration FDA, Bethesda, Maryland, USA
    PLoS Pathog 8:e1002920. 2012
    ..The ability to generate high affinity antibodies could have significant impact on the elucidation of age-specific antibody responses following vaccination and eventual clinical efficacy and disease outcome...
  4. pmc H5N1-SeroDetect EIA and rapid test: a novel differential diagnostic assay for serodiagnosis of H5N1 infections and surveillance
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bldg 29B, Rm 4NN02, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 85:12455-63. 2011
    ..The simple H5N1-SeroDetect ELISA and rapid tests could provide an important tool for large-scale surveillance for potential exposure to HP H5N1 strains in both humans and birds...
  5. pmc Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies
    Swati Verma
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    J Virol 86:12283-93. 2012
    ..2 viruses, as measured by SPR. This is the first study to show the role of antibody avidity for the HA1 globular head domain in reduction of viral loads in the upper respiratory tract, which could significantly reduce viral transmission...
  6. pmc Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Virol 85:1246-56. 2011
    ..Our findings suggest that functional oligomeric rHA1-based vaccines can be produced efficiently in bacterial systems and can be easily upscaled in response to a pandemic influenza virus threat...
  7. pmc H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Virol 85:10945-54. 2011
    ..These findings represent the first report describing the quality of the antibody responses in humans following AIV VLP immunization and support further development of such vaccines against emerging influenza virus strains...
  8. ncbi request reprint Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, MD 20892, USA
    Sci Transl Med 5:200ra114. 2013
    ..These findings should be considered during the evaluation of universal influenza vaccines designed to elicit HA2 stem-targeting antibodies. ..
  9. pmc Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 43:304-12. 2006
    ..Therefore, HIV-SELECTEST could be an important differential diagnostic tool for HIV vaccine trials, blood banks, and population screening worldwide...
  10. doi request reprint Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Sci Transl Med 2:15ra5. 2010
    ..Thus, MF59 adjuvant improves the immune response to a H5N1 vaccine by inducing qualitative and quantitative expansion of the antibody repertoires with protective potential...
  11. pmc MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Sci Transl Med 3:85ra48. 2011
    ..Thus, MF59 quantitatively and qualitatively enhances functional antibody responses to HA-based vaccines by improving both epitope breadth and binding affinity, demonstrating the added value of such adjuvants for influenza vaccines...
  12. pmc HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Microbiol 48:281-5. 2010
    ..A rapid test version of the HIV-Selectest was developed. Both assays detected HIV antibodies in men and women within 2 to 4 weeks of infection, with sensitivity similar to third-generation EIAs...
  13. pmc Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children
    Nitin Verma
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    J Virol 86:5515-22. 2012
    ..These findings may help explain the age-related morbidity and mortality pattern observed during the H1N1pdm09 pandemic...
  14. pmc Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Med 6:e1000049. 2009
    ..Characterizing the B cell responses in convalescent individuals could help in the design of future vaccines and therapeutics...
  15. pmc A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells
    Hanxin Lu
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 6:e17297. 2011
    ..Generation of stably transfected mammalian cells secreting properly folded HA proteins is important for scalable controlled manufacturing...
  16. pmc Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 29:5657-65. 2011
    ..We conclude that bacterially expressed recombinant HA1 proteins can be produced rapidly and used to generate SRID potency reagents shortly after new influenza strains with pandemic potential are identified...
  17. pmc Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 5:e11548. 2010
    ..The traditional process of influenza vaccine production in eggs is time consuming and may not meet the demands of rapid global vaccination required to curtail influenza pandemic...
  18. pmc Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, Food and Drug Administration FDA, Bethesda, Maryland, United States of America
    PLoS ONE 9:e95496. 2014
    ....
  19. doi request reprint Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Infect Dis 205:610-20. 2012
    ..The H1N1 2009 influenza (H1N1pdm09) pandemic had unexpected features, including lower morbidity and mortality in elderly populations...
  20. pmc Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection
    Sandra Fuentes
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, FDA, Bethesda, MD 20892, USA
    Vaccine 31:3987-94. 2013
    ..This newly developed simple, high throughput, RSV-Luc-NeuT could be easily automated and applied in measurement of RSV neutralization titers in large vaccine trials...
  21. pmc Influenza A virus hemagglutinin trimerization completes monomer folding and antigenicity
    Javier G Magadán
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 87:9742-53. 2013
    ..Once this conformational change occurs, HA trimers themselves would not necessarily be required to induce a highly diverse neutralizing response to epitopes in the globular domain. ..
  22. pmc Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, FDA, Bethesda, MD 20892, USA
    J Virol 80:2092-9. 2006
    ..The new HIV-SELECTEST is a simple but robust diagnostic tool for easy implementation in HIV vaccine trials and blood banks worldwide...
  23. ncbi request reprint CCR5 N-terminal region plays a critical role in HIV-1 inhibition by Toxoplasma gondii-derived cyclophilin-18
    Hana Golding
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Biol Chem 280:29570-7. 2005
    ..The elucidation of the functional C-18-binding mechanism may help in the rational design of novel antiviral agents against HIV...
  24. pmc Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA
    J Virol 79:6791-800. 2005
    ..In summary, we have identified a novel peptide that closely mimics the MAb 2D7 epitope on CCR5. This peptide could be included as a potential vaccine candidate or to isolate 2D7-like human antibodies as entry inhibitors for R5 viruses...